89 results
6-K
EX-99.1
BLU
Bellus Health Inc
28 Jun 23
GSK completes acquisition of BELLUS Health
11:05am
of the COVID-19 pandemic.
Early Warning Reporting
In connection with the arrangement above, 14934792 Canada Inc., a wholly-owned subsidiary of GSK
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
. The Company introduced a global framework and guiding principles for remote work during the COVID-19 pandemic, including work from home for all employees
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
demonstrations, insurrection, national or international calamity, sabotage or terrorism, (iii) any pandemic or epidemic (including COVID-19) or other outbreak … , and any evolution or variant thereof or any related or associated epidemic, pandemic, or disease outbreak.
“Davies” means Davies Ward Phillips
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
;
our expectations regarding the ongoing COVID-19 pandemic and its impact on our business;
our expectation with respect to the cost and availability … be caused by the ongoing COVID-19 pandemic;
the absence of interruption or delays in the operations of our suppliers of components or raw materials
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
conditions, general conditions in the pharmaceutical industry, the impact of the ongoing COVID-19 pandemic on BELLUS Health’s operations, plans
6-K
EX-99.1
jpth0mo f3wh7
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.2
gc5iql99vck0edoiosj
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.1
8nbbrtv651tf1 z8
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
who8gk5 hgisbl
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.2
5fiee e1j
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
6-K
EX-99.1
aehpok2 l9wu9
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
4sdtvkjt
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
wtmqxpo
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
clf9bglo5i
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
jwwmx4k
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
6akm8rct2r
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
yqn3lb1exhyukp
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
5bd41k0az
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
gcgwkgm1 2pwbx5x
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
g03 vt6ewxwub9kvko
26 Aug 22
Registration of securities (Canada)
4:48pm